As of November 4, 2026, Karyopharm Therapeutics Inc. is a publicly traded company (Nasdaq: KPTI); its largest reported holder is RA Capital, with 9.9% on Schedule 13G/A of August 14, 2026, then Adage Capital (6.78%). The largest insider holding is Richard Paulson, the chief executive and president, with 269,747 shares (1.2% of shares outstanding), per Form 4 of May 15, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Karyopharm Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Karyopharm Therapeutics Inc. a real, registered company?
- Karyopharm Therapeutics Inc. files with the SEC under CIK 1503802 (its SEC filings).
- Its shares are listed under the ticker KPTI on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Newton, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court record: no federal case found under Karyopharm Therapeutics Inc. in our court records (as of 2026-11-04).
- Bankruptcy: Karyopharm Therapeutics Inc. and its subsidiaries filed for Chapter 11, as Karyopharm Therapeutics Inc. reported on Form 8-K on November 3, 2026 (Form 8-K, Item 1.03, filed 2026-11-03).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Anders Hove (filed 2026-09-25).
Who are Karyopharm Therapeutics Inc.'s owners and officers?
Karyopharm Therapeutics Inc.: incorporated in Delaware; business address in Newton, Massachusetts; industry Pharmaceutical Preparations (Form 8-K, 2026-11-03).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2022-12-08)
- : Executive Officer (Form D, 2022-12-08)
- : Executive Officer (Form D, 2022-12-08)
- : Executive Officer (Form D, 2022-12-08)
- : Executive Officer (Form D, 2022-12-08)
- : Executive Officer (Form D, 2022-12-08)
- : Executive Officer (Form D, 2022-12-08)
- : Director (Form D, 2022-12-08)
- : Director (Form D, 2022-12-08)
- : Director (Form D, 2022-12-08)
- : Director (Form D, 2022-12-08)
- : Director (Form D, 2022-12-08)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-28 | Integrated Core Strategies (US) LLC | 0.2% |
| Schedule 13G/A, 2026-10-08 | Anders Hove | 4.5% |
| Schedule 13G/A, 2026-09-25 | Anders Hove | 5.7% |
| Schedule 13G/A, 2026-09-25 | Anders Hove | 5.7% |
| Schedule 13G, 2026-09-04 | Integrated Core Strategies (US) LLC | 5.7% |
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-08-14 | Commodore Capital LP | 0% |
| Schedule 13G/A, 2026-08-12 | Adage Capital Management, L.P. | 6.78% |
| Schedule 13G/A, 2026-08-11 | The Goldman Sachs Group, Inc. | 6.3% |
| Schedule 13G, 2026-07-28 | Blackrock, Inc. | 5.6% |
| Schedule 13G/A, 2026-06-05 | T. Rowe Price Investment Management, Inc. | 6.6% |
| Schedule 13G, 2026-05-15 | Ikarian Capital, LLC | 0% |
Questions about who owns Karyopharm Therapeutics Inc.
Who owns Karyopharm Therapeutics Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Karyopharm Therapeutics Inc.: Ra Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Adage Capital Management, L.P. (6.78%, Schedule 13G/A, filed 2026-08-12), T. Rowe Price Investment Management, Inc. (6.6%, Schedule 13G/A, filed 2026-06-05), The Goldman Sachs Group, Inc. (6.3%, Schedule 13G/A, filed 2026-08-11) and Blackrock, Inc. (5.6%, Schedule 13G, filed 2026-07-28).
Who are the largest shareholders of Karyopharm Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Karyopharm Therapeutics Inc. on this page are Ra Capital Management, L.P. (9.9%), Adage Capital Management, L.P. (6.78%) and T. Rowe Price Investment Management, Inc. (6.6%).
When did Ra Capital Management, L.P. buy into Karyopharm Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13G/A, filed 2026-08-14, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Karyopharm Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Karyopharm Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Karyopharm Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Karyopharm Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 269,747 shares (1.2% of shares outstanding) (Form 4, 2026-05-15).
- , the executive vice president and chief commercial officer: 107,940 shares (0.48% of shares outstanding) (Form 4, 2026-05-15).
- , the executive vice president and chief development officer: 94,632 shares (0.42% of shares outstanding) (Form 4, 2026-07-30).
- , the executive vice president and chief legal officer: 94,398 shares (0.42% of shares outstanding) (Form 4, 2026-05-15).
- , the chief financial officer and executive vice president: 85,105 shares (0.38% of shares outstanding) (Form 4, 2026-02-04).
Shares outstanding: 22,681,460 as of 2026-08-06, from the company's latest SEC cover page.
How much has Karyopharm Therapeutics Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2022-12-08 | $165M | $165M |
What is Karyopharm Therapeutics Inc.'s court and legal record?
Bankruptcy or receivership reported on Form 8-K, Item 1.03: Form 8-K, 2026-11-03 (Chapter 11).
Red flags found
a bankruptcy or receivership filing by Karyopharm Therapeutics Inc. and its subsidiaries (Form 8-K, 2026-11-03).
Keep reading
More on Karyopharm Therapeutics Inc. and the records around it.
Karyopharm Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Bankruptcy record
Companies that share a holder
- J. Wood Capital Advisors LLC also filed stake reports on 1 other company: Cyclerion Therapeutics, Inc. (Oct 2026)
- ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Athira Pharma, Inc. (Aug 2026), enGene Therapeutics Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026)
- Opaleye Management Inc. also filed stake reports on 11 other companies: Grace Therapeutics, Inc. (Aug 2026), Pasithea Therapeutics Corp. (Jul 2026), Q32 Bio Inc. (Jul 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/karyopharm-therapeutics